Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

News Conference News ESC 2025

HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients

Caitlin E. Cox

September 01, 2025

News Conference News ACC 2025

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

Caitlin E. Cox

March 29, 2025

News Opinion CV Team Dispatch

November 2024 Dispatch for the CV Team

L.A. McKeown

November 26, 2024

News Conference News ESC 2022

DANCAVAS: Food for Thought as CV Screening in Older Men Misses Mark

L.A. McKeown

August 30, 2022

News Conference News

AXIOMATIC-TKR: Milvexian Promising for VTE Prevention

L.A. McKeown

November 15, 2021

News Daily News

Blood Clots After COVID-19 Vaccination Linked to Immune Response: UK Report

Michael O'Riordan

April 16, 2021

News Daily News

Papers Confirm Rare Thrombocytopenia Link to AstraZeneca Vaccine

Shelley Wood

April 09, 2021

News Daily News

Longer Patency, Fewer Repeat Procedures With Paclitaxel DCBs in Dialysis Patients

L.A. McKeown

August 21, 2020

News Conference News ACC 2020

Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients

L.A. McKeown

April 01, 2020

News Daily News

Liberal IVC Filter Use Not Warranted in Severe Trauma Patients

Shelley Wood

July 08, 2019

News Daily News

NOACs Significantly Curb Risk of VTE in Cancer Patients

L.A. McKeown

December 06, 2018

News Conference News ESC 2018

MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis

Todd Neale

August 26, 2018

News Daily News

Aspirin Switch for VTE Prevention After Hip/Knee Arthroplasty: Safe, Effective, and Cost-Saving in EPCAT II

Michael O'Riordan

February 21, 2018

News Daily News

Según los Investigadores, Contemplar de Embolismo Pulmonar por Síncope Inexplicado es ‘Absolutamente Obligatorio.’

Michael O'Riordan

October 24, 2016

News Daily News

Considering Pulmonary Embolism for Unexplained Syncope Is ‘Absolutely Mandatory,’ Investigators Say

Michael O'Riordan

October 24, 2016

News Daily News

Even Without Proof of Benefit, 1 in 6 Patients Still Given Vena Caval Filters

Yael L. Maxwell

February 29, 2016

News Daily News

Similar Efficacy, Less Bleeding With Dabigatran vs. Warfarin in VTE Patients

Yael L. Maxwell

January 01, 2014

News Daily News

Eficacia Similar y Menos Hemorragias con Dabigatran que con Warfarina en Pacientes TEV

Yael L. Maxwell

January 01, 2014

News Daily News

El Apixaban No es Inferior a la Terapia Estándar en el Tratamiento de los Tromboembolismos Venosos Agudos

L.A. McKeown

July 05, 2013

News Daily News

Apixaban Noninferior to Standard Therapy for Acute Venous Thromboembolism

L.A. McKeown

July 05, 2013

Advertisement

HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

November 2024 Dispatch for the CV Team

DANCAVAS: Food for Thought as CV Screening in Older Men Misses Mark

AXIOMATIC-TKR: Milvexian Promising for VTE Prevention

Blood Clots After COVID-19 Vaccination Linked to Immune Response: UK Report

Papers Confirm Rare Thrombocytopenia Link to AstraZeneca Vaccine

Longer Patency, Fewer Repeat Procedures With Paclitaxel DCBs in Dialysis Patients

Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients

Liberal IVC Filter Use Not Warranted in Severe Trauma Patients

NOACs Significantly Curb Risk of VTE in Cancer Patients

MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis

Aspirin Switch for VTE Prevention After Hip/Knee Arthroplasty: Safe, Effective, and Cost-Saving in EPCAT II

Según los Investigadores, Contemplar de Embolismo Pulmonar por Síncope Inexplicado es ‘Absolutamente Obligatorio.’

Considering Pulmonary Embolism for Unexplained Syncope Is ‘Absolutely Mandatory,’ Investigators Say

Even Without Proof of Benefit, 1 in 6 Patients Still Given Vena Caval Filters

Similar Efficacy, Less Bleeding With Dabigatran vs. Warfarin in VTE Patients

Eficacia Similar y Menos Hemorragias con Dabigatran que con Warfarina en Pacientes TEV

El Apixaban No es Inferior a la Terapia Estándar en el Tratamiento de los Tromboembolismos Venosos Agudos

Apixaban Noninferior to Standard Therapy for Acute Venous Thromboembolism

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content